Stocks in Focus: Marvell Technology Group Ltd. (NASDAQ:MRVL), Starbucks Corporation (NASDAQ:SBUX), Federated National Holding Company (NASDAQ:FNHC), Seattle Genetics, Inc. (NASDAQ:SGEN), Neostem (NASDAQ:NBS)

Marvell Technology Group Ltd. (NASDAQ:MRVL) belongs to Technology sector. Its net profit margin is 11.70% and weekly performance is 4.24%. On last trading day company shares ended up $14.01. Marvell Technology Group Ltd. (NASDAQ:MRVL) distance from 50-day simple moving average (SMA50) is -3.83%. Marvell Technology Group Ltd. (NASDAQ:MRVL) today announced Avastar 88W8997, the industry’s smallest, most power efficient, MU-MIMO wireless connectivity combo for enterprise and consumer markets. The 88W8997 is the industry’s first 28nm 2×2 802.11ac Wave-2 combo with full support for Bluetooth 4.2, as well as additional features anticipated to be in the future Bluetooth 5.0 release.

Starbucks Corporation (NASDAQ:SBUX) shares moved down -0.94% in last trading session and ended the day at $51.73. SBUX Gross Margin is 30.80% and its return on assets is 22.60%. Starbucks Corporation (NASDAQ:SBUX) quarterly performance is 10.41%. Starbucks Corporation (NASDAQ:SBUX) recently announced the pricing of senior notes worth $500 million due 2022 and $350 million due 2045. The $500 million offering carries an interest rate of 2.700%, while the $350 million offering carries an interest rate of 4.300%. The offering is expected to close on Jun 10, 2015.

On 02 June, Federated National Holding Company (NASDAQ:FNHC) shares moved down -1.44% and was closed at $25.32. FNHC EPS growth in last 5 year was 34.00%. Federated National Holding Company (NASDAQ:FNHC) year to date (YTD) performance is 4.93%. JMP Securities began coverage on shares of Federated National Holding (NASDAQ:FNHC) in a report. The firm issued a market perform rating on the stock.

Seattle Genetics, Inc. (NASDAQ:SGEN) ended the last trading day at $45.52. Company weekly volatility is calculated as 4.19% and price to cash ratio as 19.21. Seattle Genetics, Inc. (NASDAQ:SGEN) showed a weekly performance of 6.33%. Seattle Genetics Inc. (NASDAQ:SGEN) today announced several ADCETRIS (brentuximab vedotin) data presentations in the AETHERA post-transplant consolidation setting for Hodgkin lymphoma (HL) and in frontline diffuse large B-cell lymphoma (DLBCL) at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting being held May 29 to June 2 2015 in Chicago IL. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30 which is expressed in classical HL and systemic anaplastic large cell lymphoma (sALCL) and several other types of non-Hodgkin lymphoma.

Neostem, Inc. (NASDAQ:NBS) shares increased 6.60% in last trading session and ended the day at $2.26. NBS Gross Margin is 11.10% and its return on assets is -47.40%. Neostem, Inc. (NASDAQ:NBS) quarterly performance is -43.36%. Neostem, Inc. (NASDAQ:NBS) on May 29, 2015, declared that it plans to change its corporate name to Caladrius Biosciences, Inc. (“Caladrius”), effective June 8, 2015. “The upcoming name change and rebranding of NeoStem are important steps to outwardly reflect what those in the industry and our clients already know about the company — that we are a leader in the innovation, development and manufacture of cell-based individualized medicine and immuno-oncology, with extensive experience in dozens of cell types as well as a pipeline using many cells of the immune system beyond stem cells,” said Dr. David J. Mazzo, Chief Executive Officer of NeoStem.

Leave a Reply

Your email address will not be published. Required fields are marked *